Drugging histone methyltransferases in cancer - Génétique et Biologie du Développement Accéder directement au contenu
Article Dans Une Revue Current Opinion in Chemical Biology Année : 2020

Drugging histone methyltransferases in cancer

Résumé

Targeting chromatin-modifying enzymes is a promising strategy for cancer treatment. The antitumor effectivity of compounds inhibiting histone methyltransferases - mainly EZH2 - is currently being tested in phase I/II clinical trials, some of them showing positive results in hematological malignancies and solid tumors of specific mutational background. In this review, we aim at highlighting the recent advances in the field of histone methyltransferase inhibitors and describing the challenges that need to be addressed for their successful implementation in the clinics.
Fichier principal
Vignette du fichier
S1367593119301309.pdf (16.45 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03489962 , version 1 (21-07-2022)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Laia Richart, Raphaël Margueron. Drugging histone methyltransferases in cancer. Current Opinion in Chemical Biology, 2020, 56, pp.51 - 62. ⟨10.1016/j.cbpa.2019.11.009⟩. ⟨hal-03489962⟩
29 Consultations
13 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More